Search company, investor...

Predict your next investment

Family Office
apeiron-investments.com

Investments

24

Portfolio Exits

3

About Apeiron Investment Group

Apeiron Investment Group is the family office of Christian Angermayer. The Group's focus by region lies on Germany and Africa. The sector focus lies on Financial Services, Internet & Technology, Life Sciences, Media, Real Estate, and Natural Resources.

Headquarters Location

Want to inform investors similar to Apeiron Investment Group about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Apeiron Investment Group News

This investor predicts a wave of biotech bankruptcies — and thinks it could be a 'canary in the coal mine' for other industries

Dec 30, 2022

That's according to billionaire biotech investor Christian Angermayer, founder of Apeiron Investment Group. Angermayer told Insider that as the economic slowdown continues into 2023, he expects a wave of biotech companies will fail to receive funding and eventually go bankrupt. "There will be some great science that unfortunately will not come to fruition," he said. Most biotech companies are still pre-revenue, which means they are hit hard and fast when economic slowdowns occur. That's because companies developing new drugs don't tend to make any money until the drug comes to market. And to make that happen, the companies need an average of ten years of research , and often more than one billion dollars , to fund clinical trials and generate data that shows the drug is safe and works on patients. "Unfortunately for biotech and pre-revenue companies, they are a canary in the coalmine," Angermayer said. "Inflation hits non-cash flow positive companies hardest and first since the market is always forward-looking, and only later starts to eat the margins of cash-generating enterprises." The biotech industry has been struggling since last year and it's only now that many other companies, like those in big tech, are starting to catch up. Soon, economists predict that the whole country could face a recession. This pattern has been seen before. In the massive 2008 recession, biotech companies were hit hard and early as venture capital funding faltered. Tens of thousands of jobs were cut and a host of research efforts were either paused or abandoned all together. We're already seeing a wave of biotech layoffs in 2022. At least 118 companies in the space have laid off staff this year, according to a layoff tracker published by Fierce Biotech. Several years after the 2008 recession, the biotech sector did bounce back. In 2011, biotech companies raised $4.82 billion from venture capitalists, a significant increase from prior years according to Reuters . And despite a tough economic landscape, some companies may still be able to convince investors that they're worth taking a chance on right now. Angermayer said he believes that VCs with an eye for the future will still be willing to place big bets into the right companies. And other VCs previously told Insider  that they were beginning to adjust their priorities amid the economic downturn, prioritizing startups with a quicker path to generating revenue rather than placing large bets on interesting but risky investments. Subscribe to push notifications

Apeiron Investment Group Investments

24 Investments

Apeiron Investment Group has made 24 investments. Their latest investment was in nextmarkets as part of their Private Equity on April 4, 2023.

CBI Logo

Apeiron Investment Group Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/18/2023

Private Equity

nextmarkets

$10.96M

Yes

3

10/25/2022

Series B

Alto Neuroscience

$35M

No

9

2/22/2022

PIPE

The Healing Company

$10M

Yes

2

10/26/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

10/14/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/18/2023

10/25/2022

2/22/2022

10/26/2021

10/14/2021

Round

Private Equity

Series B

PIPE

Series C

Series A

Company

nextmarkets

Alto Neuroscience

The Healing Company

Subscribe to see more

Subscribe to see more

Amount

$10.96M

$35M

$10M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

9

2

10

10

Apeiron Investment Group Portfolio Exits

3 Portfolio Exits

Apeiron Investment Group has 3 portfolio exits. Their latest portfolio exit was ATAI Life Sciences on June 18, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/18/2021

IPO

$99M

Public

17

5/11/2021

Corporate Majority

Subscribe to see more

$99M

Subscribe to see more

10

2/4/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/18/2021

5/11/2021

2/4/2021

Exit

IPO

Corporate Majority

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

17

10

10

Apeiron Investment Group Team

2 Team Members

Apeiron Investment Group has 2 team members, including , .

Name

Work History

Title

Status

Christian Angermayer

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Christian Angermayer

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Status

Current

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.